I. Dale

发表

Phosphorylation-dependent BRD4 dimerization and implications for therapeutic inhibition of BET family proteins

Andrew J. Bannister, G. Degliesposti, T. Jowitt, 2021, Communications biology.

Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses?

I. Dale, J. D. Hothersall, Alastair J. H. Brown, 2016, Drug discovery today.

Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative.

P. Charlton, I. Dale, R. Callaghan, 1998, British Journal of Cancer.

Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells.

T. Bradshaw, A. Gescher, I. Dale, 1989, Cancer research.

Structural Basis for Targeting the Folded P-Loop Conformation of c-MET

C. Stubbs, I. Dale, U. Börjesson, 2020, ACS medicinal chemistry letters.

Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells

A. Gescher, I. Dale, Andreas Gescher, 1989, International journal of cancer.

Studies on quinazolinones as dual inhibitors of Pgp and MRP1 in multidrug resistance.

T. Hancox, P. Charlton, I. Dale, 2002, Bioorganic & medicinal chemistry letters.

Regulation of c-fos transcription by chemopreventive isoflavonoids and lignans in MDA-MB-468 breast cancer cells.

T. Gant, A. Gescher, I. Dale, 1998, European journal of cancer.

Synthesis and biological evaluation of a series of flavones designed as inhibitors of protein tyrosine kinases.

P. Groundwater, J. Hickman, I. Dale, 1992, Anti-cancer drug design.

Protein kinase C--a novel target for rational anti-cancer drug design?

A. Gescher, I. Dale, 1989, Anti-cancer drug design.

Phosphorylation-dependent BRD4 dimerization and implications for therapeutic inhibition of BET family proteins

G. Degliesposti, T. Jowitt, F. Malvezzi, 2021, Communications Biology.

Discovery of a Potent and Selective ATAD2 Bromodomain Inhibitor with Antiproliferative Activity in Breast Cancer Models.

Nichola L. Davies, A. Rabow, S. Guichard, 2022, Journal of medicinal chemistry.

Discovery of a selective c-MET inhibitor with a novel binding mode.

R. Jetson, C. Stubbs, I. Dale, 2022, Bioorganic & medicinal chemistry letters.

Effect of two inducers of cellular differentiation on the glutathione status of human HL-60 promyelocytic leukaemia and A549 lung carcinoma cells.

A. Gescher, I. Dale, C. M. Lazenby, 1987, Biochemical pharmacology.

Sustained wash-resistant receptor activation responses of GPR119 agonists.

James S. Scott, I. Dale, J. D. Hothersall, 2015, European journal of pharmacology.

Selective CRAF Inhibition Elicits Transactivation.

J. Chin, Andrew P Thomas, I. Dale, 2021, Journal of the American Chemical Society.

In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance

P. Charlton, S. Eccles, I. Dale, 1999, British Journal of Cancer.

Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation Kinetics

A. IJzerman, D. Guo, M. Waring, 2017, Molecular Pharmacology.

Structure-Activity Relationships of the Sustained Effects of Adenosine A 2 A Receptor Agonists Driven by Slow Dissociation Kinetics s

A. IJzerman, D. Guo, M. Waring, 2016 .

Potent and selective bivalent inhibitors of BET bromodomains.

A. Dulak, A. Rabow, M. Waring, 2016, Nature chemical biology.

Structural Basis for Targeting the Folded P-Loop Conformation of c-MET

C. Stubbs, I. Dale, U. Börjesson, 2020, ACS medicinal chemistry letters.

Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET Inhibitors

E. Hennessy, C. Koh, C. Stubbs, 2019, ACS medicinal chemistry letters.

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

G. Mills, A. Dulak, A. Rabow, 2016, Molecular Cancer Therapeutics.

Discovery and Optimization of the First ATP Competitive Type-III c-MET Inhibitor

E. Hennessy, T. Moss, C. Stubbs, 2023, Journal of medicinal chemistry.

Studies on bioactive compounds. 13. Synthesis and lack of growth-inhibitory properties of cyclohexane-1,2,4-triol 1,2-diesters, which resemble ring C of the phorbol ester molecule.

C. Laughton, A. Gescher, I. Dale, 1989, Journal of medicinal chemistry.